Navigation Links
iTherX Initiates Phase 1b Study of First-in-Class Hepatitis C Virus Entry Inhibitor ITX-5061
Date:3/15/2011

SAN DIEGO, March 15, 2011 /PRNewswire/ -- iTherX, a pharmaceutical company dedicated to discovering and developing a new class of therapies for hepatitis C, today announced that it has commenced patient recruitment in an open-label, proof-of-concept Phase 1b study of its lead compound ITX-5061 in liver transplant patients with hepatitis C virus infection (HCV).  ITX-5061 represents a first-in-class compound that inhibits entry of the hepatitis C virus into liver cells.

"ITX-5061 possesses a unique mechanism of action that prevents the hepatitis C virus from entering liver cells and has demonstrated potent preclinical antiviral activity against all HCV genotypes.In addition, it has already demonstrated safety in more than 280 subjects," said Jeffrey McKelvy, PhD, MD, President and Chief Executive Officer of iTherX.  "We hope ITX-5061 will significantly improve long-term transplant outcomes."

The primary objective of the Phase 1b clinical trial will be to assess the safety and tolerability of ITX-5061 in liver transplant patients.  The study will also assess HCV viral load for three months after liver transplantation to determine if ITX-5061 has any immediate and/or sustained impact on viral kinetics in treated patients. Approximately 20 patients will be enrolled into one of two cohorts:  one group will receive supportive care only, while the second cohort will also receive ITX-5061 at a150 mg daily dose for seven days.  The trial is being conducted at the University of Birmingham, UK under the direction of David Mutimer, MBBS, MD, FRACP, FRCP, Reader in Hepatology at Birmingham University and Consultant Hepatologist to the Birmingham QE Hospital Liver and Hepatobiliary Unit.

Preclinical studies have shown ITX-5061 to be a potent and selective inhibitor of HCV entry into hepatocytes, capable of preventing virus binding/fusion and cell to cell spread, suggesting ITX-5061  may reduce re-infection rates followi
'/>"/>

SOURCE iTherX
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Inovio Pharmaceuticals Partner ChronTech Initiates Phase II Clinical Trial of Hepatitis C Virus DNA Vaccine Using Inovios Electroporation Delivery Technology
2. Conatus Pharmaceuticals Initiates Confirmatory Phase 2 Clinical Trial of CTS-1027 for the Treatment of Hepatitis C Virus (HCV)
3. New Mexico Software Initiates Medical Second Opinion Service via Telemedicine for Remote Consultation Review
4. Tarsa Therapeutics Completes Phase III Trial of its Oral Calcitonin for Treatment of Postmenopausal Osteoporosis and Initiates Phase II Trial in Osteoporosis Prevention
5. Amicus Therapeutics Initiates Phase 2 Clinical Trial Evaluating Amigal™ Co-administered with Enzyme Replacement Therapy
6. American Regent Initiates Nationwide Voluntary Recall of Potassium Phosphates Injection, USP, 15 mM/5 mL Phosphorus; 22 mEq/5 mL Potassium, 5 mL Single Dose Vial, Lot # 0048 Due to Translucent Visible Particles
7. American Regent Initiates Nationwide Voluntary Recall of Sodium Thiosulfate Injection, USP
8. BioMarin Initiates Pivotal Phase 3 Trial for GALNS for the Treatment of MPS IVA
9. Zacks Investment Research Initiates Coverage on Viral Genetics
10. ChemoCentryx Initiates Phase I Clinical Trial of CCX832, the First Small Molecule Inhibitor of ChemR23
11. BioMarin Initiates Phase 1/2 Trial for BMN 701 for the Treatment of Pompe Disease
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/6/2015)... Moerae Matrix, a clinical stage biotechnology ... inflammation and fibrosis, today announced the appointment of ... Medical Officer. Dr. Bradford will ... which include a pipeline of therapies for pulmonary ... is an accomplished strategist and scientist with extensive ...
(Date:7/6/2015)... , July 6, 2015 Celtaxsys, Inc., a ... including those with rare and orphan inflammatory disease indications, ... U.S. Food and Drug Administration (FDA) to begin a ... acebilustat (CTX-4430), in adult CF patients in the US. ... Europe will be filed soon after. ...
(Date:7/6/2015)... --  Cepheid (Nasdaq: CPHD ) today announced that ... quarter ended June 30, 2015 on Thursday, July 23, ... The Company will host a management presentation at 2 ... discuss the results.  To access the live webcast, please ... 15 minutes before the scheduled start time to download ...
Breaking Medicine Technology:Moerae Matrix, Inc. (Moerae) Appoints Bill Bradford, M.D., PhD, as Chief Medical Officer 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 2Celtaxsys, Inc. Gains FDA Clearance for Landmark Phase 2 Trial of Anti-Inflammatory Treatment for Cystic Fibrosis (CF) 3
... 2011 VolitionRX Limited ("Volition") (VNRX.OB), ... diagnostic tests, is pleased to announce that its ... signed a contract which is expected to provide ... commissioned to develop epigenetic profiling signatures from blood. ...
... Technology Services successfully implemented advanced process technology for ... in Shanghai, China, using Intergraph® integrated design and ... solvent and energy consumption as well as operating ... http://photos.prnewswire.com/prnh/20081211/DECLOGO) These results are achieved, among ...
Cached Medicine Technology:VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures 2VolitionRX Subsidiary Enters Into its First Revenue-Generating Agreement to Profile Blood-Based Epigenetic Signatures 3Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China 2Intergraph® Technology Enables Bayer Technology Services to Engineer New Plant in China 3
(Date:7/6/2015)... Florida (PRWEB) , ... July 06, 2015 , ... MD ... on Monday, July 6. The newly constructed urgent care center will serve residents and ... , In addition to being MD Now’s 22nd South Florida location, the new facility ...
(Date:7/6/2015)... ... July 06, 2015 , ... The School ... funds to support a three-year effort to reduce rates of diabetes and cardiovascular ... in partnership with the Morehouse School of Medicine’s Prevention Research Center and the ...
(Date:7/6/2015)... ... 06, 2015 , ... Promero, a leading cloud hosting provider ... IP contact center solution hosted by Promero. Randstad Technologies,a leading talent and ... call center platform. , Promero will implement and manage the private cloud ...
(Date:7/6/2015)... ... July 06, 2015 , ... Thanks to donations and a ... received the Music & Memory Certification for hospice patients and adult day center participants. ... not only to patients but also to their families and volunteers. Music & Memory ...
(Date:7/5/2015)... ... 06, 2015 , ... City Sports, the Boston-based specialty sporting goods retailer, has ... for first-time triathletes this summer with ethos, the owner and operator of the Boston ... at 6:00 p.m. at the North End Greenway. The event will help new triathletes ...
Breaking Medicine News(10 mins):Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 2Health News:MD Now Urgent Care Opens its Fourth Miami-Dade County Facility in Cutler Bay 3Health News:Georgia State, Morehouse Partner To Tackle Diabetes, Heart Disease In Atlanta’s Minority Communities 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 2Health News:Aspect Software Unified IP, Hosted by Promero, Selected by Randstad Technologies 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 2Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 3Health News:Music & Memory Program Brings Joy and Excitement to Hospice Patients 4Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 2Health News:Sporting Goods Retailer City Sports Renews Partnership with Boston Triathlon 3
... Technologies(R),Inc. (OTC Bulletin Board: GLOB), an international ... its Wyndgate,Technologies(R) ("Wyndgate"), division will be a ... Transfusion Medicine Expo (TXPO). (Logo: ... 1947, is a leader in the development ...
... for smokers, experts say , THURSDAY, Oct. 11 (HealthDay News) ... that could give doctors early warning of lung cancer. , ... 104 people with different types of lung cancer and 50 ... autoantibodies -- immune system proteins that are directed at the ...
... Oridion,Systems, Ltd. - (SWX: ORIDN) introduces ... patient safety. This new launch takes ... in San Francisco, CA. Smart Capnography ... new SARA(TM) software for improved alarm management.,Microstream ...
... ... cold medicines for children age ... 2 and older,- Further evaluation of these oral ... 19 FDA advisory committee meeting, WASHINGTON, Oct. 11 The Consumer Healthcare Products,Association ...
... no longer afford to,ignore the growing obesity epidemic. ... on obesity-attributable health care(1). In addition, an,estimated 39 ... each,year(2). Other costs of obesity in the workplace ... Today, business leaders, healthcare industry professionals and,policymakers will ...
... concentrated Tylenol(R) Infants, Drops Plus Cold ... ... WASHINGTON, Pa., Oct. 11 McNeil Consumer,Healthcare, a division of McNeil-PPC, ... and cold products,from the market. When used as directed, these medicines ...
Cached Medicine News:Health News:Global Med Technologies(R), Inc.'s Division, Wyndgate Technologies(R), to Exhibit at 60th Annual AABB Conference 2Health News:Global Med Technologies(R), Inc.'s Division, Wyndgate Technologies(R), to Exhibit at 60th Annual AABB Conference 3Health News:Immune Proteins Warn of Early Lung Cancer 2Health News:Oridion Introduces New Smart Capnography System for Improved Patient Safety 2Health News:Oridion Introduces New Smart Capnography System for Improved Patient Safety 3Health News:Oridion Introduces New Smart Capnography System for Improved Patient Safety 4Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 2Health News:Makers of OTC Cough and Cold Medicines Announce Voluntary Withdrawal of Oral Infant Medicines 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 2Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 3Health News:Experts Urge Businesses to 'Get Real' About Obesity Impact 4Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 2Health News:McNeil Consumer Healthcare is Voluntarily Withdrawing Infants' Cough and Cold Products: 3
... Cronin, Inc. is a ... Footwear, Orthopedic Softgoods, and ... Our products are of ... available in the USA ...
... Marlin' Cervical Orthosis ensures ... semirigid molded polyethylene anterior frame ... allows free air flow and ... facilitates height adjustment. For added ...
... Aspen® Cervical Collars improves patient compliance, ... costs. Adjusts to user's anatomy, wicks ... head weight to shoulders and upper ... Front and back airflow openings. Adjustable ...
... Designed with patient need and comfort ... Appliance) family of products effectively address ... The Chairback frame attachment provides optimal ... (LSO) provides superior support for patient ...
Medicine Products: